Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis.
The main objective of this study was to utilize high field (7T) in vivo proton magnetic resonance imaging to increase the ability to detect metabolite changes in people with ALS, specifically, to quantify levels of glutamine and glutamine separately. The second objective of this study was to correla...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5428977?pdf=render |
id |
doaj-8eb5ec18b8dc4a2caa5f1c942521fc7c |
---|---|
record_format |
Article |
spelling |
doaj-8eb5ec18b8dc4a2caa5f1c942521fc7c2020-11-24T22:11:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01125e017768010.1371/journal.pone.0177680Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis.Nazem AtassiMaosheng XuChristina TriantafyllouBoris KeilRobert LawsonPaul CernasovElena RattiChristopher J LongSabrina PaganoniAlyssa MurphyNouha SalibiRavi SeethamrajuBruce RosenEva-Maria RataiThe main objective of this study was to utilize high field (7T) in vivo proton magnetic resonance imaging to increase the ability to detect metabolite changes in people with ALS, specifically, to quantify levels of glutamine and glutamine separately. The second objective of this study was to correlate metabolic markers with clinical outcomes of disease progression. 13 ALS participants and 12 age-matched healthy controls (HC) underwent 7 Tesla MRI and MRS. Single voxel MR spectra were acquired from the left precentral gyrus using a very short echo time (TE = 5 ms) STEAM sequence. MRS data was quantified using LCModel and correlated to clinical outcome markers. N-acetylaspartate (NAA) and total NAA (tNA, NAA + NAAG) were decreased by 17% in people with ALS compared to HC (P = 0.004 and P = 0.005, respectively) indicating neuronal injury and/or loss in the precentral gyrus. tNA correlated with disease progression as measured by forced vital capacity (FVC) (P = 0.014; Rρ = 0.66) and tNA/tCr correlated with overall functional decline as measured by worsening of the ALS Functional Rating Scale-Revised (ALSFRS-R) (P = 0.004; Rρ = -0.74). These findings underscore the importance of NAA as a reliable biomarker for neuronal injury and disease progression in ALS. Glutamate (Glu) was 15% decreased in people with ALS compared to HC (P = 0.02) while glutamine (Gln) concentrations were similar between the two groups. Furthermore, the decrease in Glu correlated with the decrease in FVC (P = 0.013; Rρ = 0.66), a clinical marker of disease progression. The decrease in Glu is most likely driven by intracellular Glu loss due to neuronal loss and degeneration. Neither choline containing components (Cho), a marker for cell membrane turnover, nor myo-Inositol (mI), a suspected marker for neuroinflammation, showed significant differences between the two groups. However, mI/tNA was correlated with upper motor neuron burden (P = 0.004, Rρ = 0.74), which may reflect a relative increase of activated microglia around motor neurons. In summary, 7T 1H MRS is a powerful non-invasive imaging technique to study molecular changes related to neuronal injury and/or loss in people with ALS.http://europepmc.org/articles/PMC5428977?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nazem Atassi Maosheng Xu Christina Triantafyllou Boris Keil Robert Lawson Paul Cernasov Elena Ratti Christopher J Long Sabrina Paganoni Alyssa Murphy Nouha Salibi Ravi Seethamraju Bruce Rosen Eva-Maria Ratai |
spellingShingle |
Nazem Atassi Maosheng Xu Christina Triantafyllou Boris Keil Robert Lawson Paul Cernasov Elena Ratti Christopher J Long Sabrina Paganoni Alyssa Murphy Nouha Salibi Ravi Seethamraju Bruce Rosen Eva-Maria Ratai Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis. PLoS ONE |
author_facet |
Nazem Atassi Maosheng Xu Christina Triantafyllou Boris Keil Robert Lawson Paul Cernasov Elena Ratti Christopher J Long Sabrina Paganoni Alyssa Murphy Nouha Salibi Ravi Seethamraju Bruce Rosen Eva-Maria Ratai |
author_sort |
Nazem Atassi |
title |
Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis. |
title_short |
Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis. |
title_full |
Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis. |
title_fullStr |
Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis. |
title_full_unstemmed |
Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis. |
title_sort |
ultra high-field (7tesla) magnetic resonance spectroscopy in amyotrophic lateral sclerosis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
The main objective of this study was to utilize high field (7T) in vivo proton magnetic resonance imaging to increase the ability to detect metabolite changes in people with ALS, specifically, to quantify levels of glutamine and glutamine separately. The second objective of this study was to correlate metabolic markers with clinical outcomes of disease progression. 13 ALS participants and 12 age-matched healthy controls (HC) underwent 7 Tesla MRI and MRS. Single voxel MR spectra were acquired from the left precentral gyrus using a very short echo time (TE = 5 ms) STEAM sequence. MRS data was quantified using LCModel and correlated to clinical outcome markers. N-acetylaspartate (NAA) and total NAA (tNA, NAA + NAAG) were decreased by 17% in people with ALS compared to HC (P = 0.004 and P = 0.005, respectively) indicating neuronal injury and/or loss in the precentral gyrus. tNA correlated with disease progression as measured by forced vital capacity (FVC) (P = 0.014; Rρ = 0.66) and tNA/tCr correlated with overall functional decline as measured by worsening of the ALS Functional Rating Scale-Revised (ALSFRS-R) (P = 0.004; Rρ = -0.74). These findings underscore the importance of NAA as a reliable biomarker for neuronal injury and disease progression in ALS. Glutamate (Glu) was 15% decreased in people with ALS compared to HC (P = 0.02) while glutamine (Gln) concentrations were similar between the two groups. Furthermore, the decrease in Glu correlated with the decrease in FVC (P = 0.013; Rρ = 0.66), a clinical marker of disease progression. The decrease in Glu is most likely driven by intracellular Glu loss due to neuronal loss and degeneration. Neither choline containing components (Cho), a marker for cell membrane turnover, nor myo-Inositol (mI), a suspected marker for neuroinflammation, showed significant differences between the two groups. However, mI/tNA was correlated with upper motor neuron burden (P = 0.004, Rρ = 0.74), which may reflect a relative increase of activated microglia around motor neurons. In summary, 7T 1H MRS is a powerful non-invasive imaging technique to study molecular changes related to neuronal injury and/or loss in people with ALS. |
url |
http://europepmc.org/articles/PMC5428977?pdf=render |
work_keys_str_mv |
AT nazematassi ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT maoshengxu ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT christinatriantafyllou ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT boriskeil ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT robertlawson ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT paulcernasov ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT elenaratti ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT christopherjlong ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT sabrinapaganoni ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT alyssamurphy ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT nouhasalibi ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT raviseethamraju ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT brucerosen ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis AT evamariaratai ultrahighfield7teslamagneticresonancespectroscopyinamyotrophiclateralsclerosis |
_version_ |
1725804525163380736 |